661 related articles for article (PubMed ID: 12751917)
21. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.
Cribbs DH
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):207-16. PubMed ID: 20205639
[TBL] [Abstract][Full Text] [Related]
22. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.
Neumann U; Rueeger H; Machauer R; Veenstra SJ; Lueoend RM; Tintelnot-Blomley M; Laue G; Beltz K; Vogg B; Schmid P; Frieauff W; Shimshek DR; Staufenbiel M; Jacobson LH
Mol Neurodegener; 2015 Sep; 10():44. PubMed ID: 26336937
[TBL] [Abstract][Full Text] [Related]
23. Probing amyloid-β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry.
Carlred L; Michno W; Kaya I; Sjövall P; Syvänen S; Hanrieder J
J Neurochem; 2016 Aug; 138(3):469-78. PubMed ID: 27115712
[TBL] [Abstract][Full Text] [Related]
24. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.
Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF
Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065
[TBL] [Abstract][Full Text] [Related]
25. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
Janus C; Pearson J; McLaurin J; Mathews PM; Jiang Y; Schmidt SD; Chishti MA; Horne P; Heslin D; French J; Mount HT; Nixon RA; Mercken M; Bergeron C; Fraser PE; St George-Hyslop P; Westaway D
Nature; 2000 Dec 21-28; 408(6815):979-82. PubMed ID: 11140685
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease.
Minami SS; Sidahmed E; Aid S; Shimoji M; Niikura T; Mocchetti I; Rebeck GW; Prendergast JS; Dealwis C; Wetzel R; Bosetti F; Matsuoka Y; Hoe HS; Turner RS
J Neuroinflammation; 2010 Sep; 7():57. PubMed ID: 20920207
[TBL] [Abstract][Full Text] [Related]
27. Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets; 2009 Apr; 8(2):114-27. PubMed ID: 19355932
[TBL] [Abstract][Full Text] [Related]
28. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
29. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
30. Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.
Maier M; Seabrook TJ; Lemere CA
Neurodegener Dis; 2005; 2(5):267-72. PubMed ID: 16909008
[TBL] [Abstract][Full Text] [Related]
31. The recent updates of therapeutic approaches against aβ for the treatment of Alzheimer's disease.
Ling S; Zhou J; Rudd JA; Hu Z; Fang M
Anat Rec (Hoboken); 2011 Aug; 294(8):1307-18. PubMed ID: 21717585
[TBL] [Abstract][Full Text] [Related]
32. An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.
Frost JL; Liu B; Rahfeld JU; Kleinschmidt M; O'Nuallain B; Le KX; Lues I; Caldarone BJ; Schilling S; Demuth HU; Lemere CA
Neurobiol Aging; 2015 Dec; 36(12):3187-3199. PubMed ID: 26453001
[TBL] [Abstract][Full Text] [Related]
33. Nardilysin prevents amyloid plaque formation by enhancing α-secretase activity in an Alzheimer's disease mouse model.
Ohno M; Hiraoka Y; Lichtenthaler SF; Nishi K; Saijo S; Matsuoka T; Tomimoto H; Araki W; Takahashi R; Kita T; Kimura T; Nishi E
Neurobiol Aging; 2014 Jan; 35(1):213-22. PubMed ID: 23954170
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer's mice.
Luo Z; Li J; Nabar NR; Lin X; Bai G; Cai J; Zhou SF; Cao C; Wang J
J Neuroimmune Pharmacol; 2012 Sep; 7(3):640-55. PubMed ID: 22684353
[TBL] [Abstract][Full Text] [Related]
35. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
[TBL] [Abstract][Full Text] [Related]
36. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
37. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
38. Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice.
Wang HC; Zhang T; Kuerban B; Jin YL; Le W; Hara H; Fan DS; Wang YJ; Tabira T; Chui DH
Neurosci Bull; 2015 Aug; 31(4):491-504. PubMed ID: 26254061
[TBL] [Abstract][Full Text] [Related]
39. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology.
Nemirovsky A; Shapiro J; Baron R; Kompaniets A; Monsonego A
J Neuroimmunol; 2012 Jun; 247(1-2):95-9. PubMed ID: 22498096
[TBL] [Abstract][Full Text] [Related]
40. Pyroglutamate-modified amyloid-β protein demonstrates similar properties in an Alzheimer's disease familial mutant knock-in mouse and Alzheimer's disease brain.
Wu G; Miller RA; Connolly B; Marcus J; Renger J; Savage MJ
Neurodegener Dis; 2014; 14(2):53-66. PubMed ID: 24158021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
